Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1412 results about "Inflammatory bowel disease" patented technology

A group of intestinal disorders that cause inflammation of the digestive tract.

Systems and methods for analysis of medical images for scoring of inflammatory bowel disease

This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.
Owner:ITERATIVE SCOPES INC

Substituted piperidinediones for targeted protein degradation

PCT designated stage expiredWO2025024521A1Organic active ingredientsAntipyreticInterstitial lung diseasePericarditis
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:MONTE ROSA THERAPEUTICS AG

Manganese dioxide nano-enzyme for treating inflammatory bowel disease as well as preparation method and application of manganese dioxide nano-enzyme

The invention relates to the field of biomedical materials, and particularly discloses a manganese dioxide nano-enzyme for treating inflammatory bowel disease as well as a preparation method and application of the manganese dioxide nano-enzyme. The preparation method of the manganese dioxide nano-enzyme comprises the following steps: uniformly mixing an organic solution containing manganese nitrate hexahydrate with a montmorillonite aqueous solution to obtain a mixed reaction solution; the pH value of the mixed reaction solution is adjusted to be under the alkaline condition through alkali liquor, a synthetic reaction is carried out, then centrifugation and washing are carried out, the montmorillonite-loaded manganese dioxide nano-enzyme is obtained, and the manganese dioxide nano-enzyme is of a lamellar structure with the length being 20-400 nm. The manganese dioxide nano enzyme has excellent activity similar to superoxide dismutase, catalase and glutathione peroxidase; meanwhile, the compound also has the capability of removing various free radicals such as DPPH and ABTS, can be used for treating the inflammatory bowel disease, and has a wide application prospect.
Owner:SOUTHWEST UNIVERSITY FOR NATIONALITIES

Lactobacillus paracasei SX-M1559 and application thereof in preparation of drugs for reducing blood sugar and lipid and resisting inflammation

The invention discloses a lactobacillus paracasei SX-M1559 strain and application thereof in preparation of drugs for reducing blood sugar and lipid and resisting inflammation, and belongs to the technical field of microorganisms. The invention discloses a lactobacillus paracasei SX-M1559, and the preservation number of the lactobacillus paracasei SX-M1559 is CCTCC (China Center For Type Culture Collection) NO: M 2025030. According to the lactobacillus paracasei SX-M1559 and the application thereof in preparation of the medicine for reducing blood sugar, blood fat and inflammation, the SX-M1559 is separated from fresh feces of long-life old people, teai county, Zhanjiang city, Guangdong province, the glucose content in a zebra fish hyperglycemia model body and the fat content in a zebra fish hyperlipidemia model body can be remarkably reduced, and the effect of reducing blood sugar, blood fat and inflammation is achieved. The invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating hyperlipidemia, diabetes mellitus and inflammatory bowel disease by utilizing the new strain SX-M1559 of the casei paracasei.
Owner:GUANGDONG MEDICAL UNIV

Bifidobacterium animalis subsp. Lactis B7 as well as composition and application thereof

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.
Owner:SICHUAN GAOFUJI BIOLOGICAL TECH

Bifidobacterium animalis subsp. Lactis C-2 with effect of improving inflammatory bowel disease and application of bifidobacterium animalis subsp. Lactis C-2

The invention relates to bifidobacterium animalis subsp. Lactis C-2 with an effect of improving inflammatory bowel diseases and application of the bifidobacterium animalis subsp. Lactis C-2. The bifidobacterium animalis subsp. Lactis C-2 is classified and named as Bifidobacterium animalis subsp. Lactis, and the preservation number of the bifidobacterium animalis subsp. Lactis C-2 is GDMCC No: 65455. The bacterial strain can inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria and optimize the composition of intestinal microorganisms by regulating the intestinal microecology, repairing the intestinal mechanical barrier, improving the intestinal immune response, inhibiting oxidative stress reaction and other action mechanisms, thereby inducing anti-inflammatory response and improving the intestinal barrier function. Therefore, the bifidobacterium animalis subsp. Lactis C-2 strain is suitable for preparing the medicine with the effect of preventing, improving or treating the inflammatory bowel disease.
Owner:CLASSY KISS YOGURT(SUZHOU) CO LTD +1

Methods of treating a patient with an inflammatory bowel disease

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.
Owner:ODYSSEY THERAPEUTICS INC

Wehononella enteritidis and application thereof

The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).
Owner:CAPITAL INST OF PEDIATRICS

Bifidobacterium breve BX-18 and application thereof in regulating intestinal flora homeostasis

The invention discloses a bifidobacterium breve BX-18 strain, and the preservation number of the bifidobacterium breve BX-18 strain is CGMCC (China General Microbiological Culture Collection Center The invention also discloses application of the bifidobacterium breve BX-18 strain in preparation of food for improving intestinal flora homeostasis and improving symptoms of inflammatory bowel diseases. The invention can be used as a probiotic preparation, can be applied to products such as pharmaceutical compositions, foods, health-care products and food additives, and is used for regulating intestinal flora and preventing and improving intestinal diseases such as inflammatory bowel diseases. The probiotic preparation provided by the invention is used as a microecological preparation for regulating intestinal flora disorder caused by the inflammatory bowel disease, and has the characteristics of simplicity in taking, no toxic action and the like.
Owner:INNER MONGOLIA AGRICULTURAL UNIVERSITY

Cluster sports enterobacter ludwigii and application thereof

The invention belongs to the technical field of new application of microorganisms, and particularly relates to enterobacter ludwigii and application of the enterobacter ludwigii in improvement of inflammatory bowel diseases. The name of the strain is Enterobacter ludwigii LS-57, the strain is preserved in the China General Microbiological Culture Collection Center on July 22, 2024, the preservation date is July 22, 2024, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.31424. The invention further discloses a preparation method of the enterobacter ludwigii LS-57. The strain has a cluster movement capability, has relatively strong adaptive capacity to the intestinal environment, can well tolerate the acidity of gastric juice, is sensitive to various common antibiotics, and has a good improvement effect on colitis.
Owner:SHANGHAI LISHAN BIOPHARMACEUTICAL CO LTD

In vitro model of inflamed intestinal barrier

The present invention relates to an intestinal epithelium model accurately reproducing the pathophysiological mechanisms observed in vivo in the context an inflammatory condition of the intestinal barrier. The model according to the present invention comprises two compartments separated by a semi-permeable membrane. The first compartment, corresponding to the apical pole of the intestinal epithelium, comprises a coculture of Caco-2 cells differentiated into enterocytes and HT29-MTX cells differentiated into goblet cells. The second compartment, corresponding to the basolateral pole of the intestinal epithelium, comprises a culture of THP-1 monocytic cells differentiated into macrophages. The model according to the present invention is characterized in that the cells contained in the first compartment produce interleukin 6 (IL-6) at a concentration of more than 100 pg / ml and interleukin 8 (IL-8) at a concentration of more than 150 pg / ml, and the cells contained in the second compartment produce tumour necrosis factor α (TNF-α) at a concentration of more than 40 pg / ml and interleukin 1β (IL-1β) at a concentration of more than 90 pg / ml. The present invention also relates to the method for obtaining this model and also to a method for selecting candidate compounds for the treatment of inflammatory bowel diseases by verifying their ability to stop the inflammation as soon as the permeability is increased, or verifying the restoration of the permeability and of the mucus layer.
Owner:UNIVERSITE DE FRANCHE COMTE

Dosage forms for Tyk2 inhibitors

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.
Owner:BRISTOL MYERS SQUIBB CO

Mannose / trimethyl chitosan modified MXene material, preparation method and application in preventing and treating inflammatory bowel disease

The invention relates to the technical field of medicines, and discloses a mannose / trimethyl chitosan modified MXene material (MTC / MXene), a preparation method and application of the mannose / trimethyl chitosan modified MXene material in prevention and treatment of inflammatory bowel diseases. The MTC / MXene material is obtained by preparing mannose-modified trimethyl chitosan and modifying the mannose-modified trimethyl chitosan on a single-layer MXene nanosheet, compared with a pure MXene material, MTC modification endows MXene with hydrophilicity, rich reaction sites are provided for drug loading, higher oxidation resistance is achieved, meanwhile, through surface functional groups and interlayer gaps of the MXene material, the MXene / MTC / MXene material can be used for preparing the drug, and the drug loading efficiency is improved. Different types of drug molecules are loaded and are used for realizing targeted delivery and controlled release of drugs.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)

Lactobacillus rhamnosus QS001 and application of lactobacillus rhamnosus QS001 in preparation of intestinal probiotic preparation

The invention discloses a strain of lactobacillus rhamnosus QS001 and application thereof in preparation of an intestinal probiotic preparation, and is characterized in that the lactobacillus rhamnosus QS001 is classified and named as lactobacillus rhamnosus, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has the preservation number of CGMCC No.29275, and has the preservation number of CGMCC No.29275. The lactobacillus rhamnosus QS001 is named as lactobacillus rhamnosus QS001 and the application of the lactobacillus rhamnosus QS001 in preparation of the intestinal probiotic preparation. According to the application of the lactobacillus rhamnosus QS001 in the aspect of preparing the intestinal probiotic preparation, active ingredients of the probiotic preparation comprise thalli of the lactobacillus rhamnosus QS001. The lactobacillus rhamnosus QS001 also has application in preparation of immune disorder regulators and medicines for improving the concentration of anti-inflammatory cytokines in colon tissues and / or reducing the concentration of proinflammatory cytokines, and has the advantages of relieving or treating inflammatory bowel diseases and regulating immune disorder.
Owner:乾生(宁波)科技有限公司

New multi-functional oligopeptides

PCT designated stage expiredWO2024260465A1Cosmetic preparationsPeptide/protein ingredientsMucosal diseaseBowels diseases
There is provided a compound of Formula I, wherein: Qa represents Z or A-Q-B, and Q is a structural fragment of Formula II,wherein: the squiggly lines, R and m have meanings given in the description, and wherein A and B have meanings given in the description, but may represent a peptide component of Formula (IV),[(W)r-Lys-X1-T-U-X2-Y] n- (W)r-Lys-X1-T-U-X2-Y (IV) (SEQ ID No: 1) in which n, r, T, W, X1, U, X2 and Y have meanings given in the description, each L independently represents a lipid as defined in the description, and D represents one or more optional montelukast moieties, which compounds are useful in medicine, including as pharmaceutical excipients, adhesives and film-forming materials and / or are useful in the treatment of conditions characterised by inflammation, including wounds, burns, and disorders of the mucosa, such as anorectal diseases, inflammatory bowel diseases, gynecological diseases and dental diseases.
Owner:ENLITISA (SHANGHAI) PHARM CO LTD

Lactobacillus plantarum strain sourced from healthy people in cold region and application of lactobacillus plantarum strain

The invention discloses a lactobacillus plantarum strain from healthy people in a cold region and application of the lactobacillus plantarum strain. The lactobacillus plantarum strain is named as PL-H1, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22286. The lactobacillus plantarum PL-H1 screened by the invention can obviously relieve the disease index, intestinal canal pathological change, inflammatory response and the like of an inflammatory bowel disease (IBD) model mouse. Moreover, compared with a standard strain WCSF1, the strain has the high metabolism characteristic of tryptophan and the function of adjusting the metabolism of IBD host intestinal tryptophan, and the curative effect of preventing and treating IBD is more remarkable. In addition, the lactobacillus plantarum strain PL-H1 can also improve the liver lipid accumulation and NAFLD activity of MCD fed mice, improve the blood lipid level and liver injury of the MCD fed mice and prevent liver fibrosis of the MCD fed mice, can be used for preventing and treating fungal infection related diseases, and is good in safety.
Owner:HARBIN MEDICAL UNIVERSITY

Attenuated artificial bear gall powder nano preparation as well as preparation method and application thereof

The invention discloses an attenuated artificial bear gall powder nano preparation, the physical structure of which is a core-shell structure, the core is zinc oxide nanoparticles, the shell is mesoporous SiO2, and artificial bear gall powder is attached to the outer surface of the shell, through the design of the core-shell structure, the dissolution of zinc ions can be reduced while efficient loading and pH response release of the artificial bear gall powder can be realized, and the toxicity of the artificial bear gall powder can be reduced. The toxicity of the preparation is reduced; the invention further discloses a preparation method which has the characteristics of simple steps, low cost and suitability for industrial production. The invention further discloses a novel application range, namely, the compound has a wide clinical application prospect in the fields of inflammatory bowel diseases and the like needing targeted anti-inflammatory treatment.
Owner:JIANGYIN AIPUYU TRADITIONAL CHINESE MEDICINE TECHNOLOGY CO LTD +1

5,6 saturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3

PCT designated stage expiredWO2024249389A2Organic chemistryPericarditisReceptor
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
Owner:MERCK SHARP & DOHME LLC

Mucosal epithelial cell targeted oral ROS responsive nano-enzyme as well as preparation method and application of mucosal epithelial cell targeted oral ROS responsive nano-enzyme

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

Application of probiotics Blauria wexlerae in improvement or treatment of children inflammatory bowel disease

The invention discloses an application of probiotics Blauria winteriae in the preparation of a medicine or food for improving or treating the inflammatory bowel disease of children, and relates to the field of medicines or foods for improving or treating the inflammatory bowel disease of children. According to the invention, the probiotic Blauria wexlerae is used as an effective component to be prepared into medically and food acceptable dosage forms, so that the children inflammatory bowel disease can be obviously improved or treated, and the application value of the probiotic is improved.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, bacteriocin, preparation method, and use

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.
Owner:INNER MONGOLIA YILI IND GROUP CO LTD

5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3

PCT designated stage expiredWO2024249539A1Organic active ingredientsOrganic chemistryPericarditisReceptor
Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
Owner:MERCK SHARP & DOHME LLC

Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.
Owner:CEDARS SINAI MEDICAL CENT +1

Health information management platform for patients with inflammatory bowel diseases

The invention discloses a health information management platform for an inflammatory bowel disease patient. The health information management platform comprises the following steps: step 1, user registration and information input; 2, data preprocessing and feature extraction; 3, constructing and training a model; step 4, a real-time prediction and early warning mechanism; according to the scheme, by actively monitoring the health data of the patient and applying the real-time analysis capability of the machine learning model, potential health problems can be recognized in advance, timely early warning is achieved, the risk of acute symptom attack is reduced, and therefore the life quality of the patient is improved, multi-dimensional data analysis is utilized, and the accuracy of the patient is improved. Customized health management suggestions are provided for each patient, individual requirements of the patient are met, the control ability of the patient to the illness state of the patient is enhanced, the treatment effect is improved, the system can provide more basis treatment suggestions for doctors through continuous learning and optimization, clinical decisions are helped to be improved, and the accuracy and effectiveness of overall treatment are improved.
Owner:THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

A Prediction System for Inflammatory Bowel Disease Treatment Based on Multimodal Data

This invention discloses a system for predicting the efficacy of inflammatory bowel disease based on multimodal data, relating to the field of medical information processing. The system includes: a multimodal data acquisition module for receiving multimodal data; a text feature extraction module for determining text feature vectors using a text feature extraction model; an endoscopic intestinal mucosal feature recognition module for determining intestinal mucosal features using an endoscopic intestinal mucosal feature recognition model; an image feature recognition module for determining imaging features using an image feature recognition model; a pathological feature extraction module for determining pathological features using a pathological recognition model; and an efficacy prediction module for predicting the efficacy of biologics based on multimodal data features using a Transformer model and fully connected layers. Compared to existing technologies, this invention achieves efficacy prediction of biologics based on the fusion of clinical, pathological, endoscopic, and imaging multimodal features, improving the accuracy and clinical rationality of diagnostic and treatment decisions.
Owner:SUN YAT SEN UNIV +1

Follow-up visit management system for patients with inflammatory bowel diseases

The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT-SEN UNIV GUANGXI HOSPITAL